167 related articles for article (PubMed ID: 34324253)
1. Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis.
Swanson KJ; Djamali A; Jorgenson MR; Misch EA; Ghaffar A; Zhong W; Aziz F; Garg N; Mohamed M; Mandelbrot D; Parajuli S
Transpl Infect Dis; 2021 Oct; 23(5):e13702. PubMed ID: 34324253
[TBL] [Abstract][Full Text] [Related]
2. The risk of cytomegalovirus infection after treatment of acute rejection in renal transplant recipients.
Jorgenson MR; Descourouez JL; Lyu B; Astor BC; Garg N; Smith JA; Mandelbrot DA
Clin Transplant; 2019 Aug; 33(8):e13636. PubMed ID: 31194887
[TBL] [Abstract][Full Text] [Related]
3. Native kidney cytomegalovirus nephritis and cytomegalovirus prostatitis in a kidney transplant recipient.
Tan SK; Cheng XS; Kao CS; Weber J; Pinsky BA; Gill HS; Busque S; Subramanian AK; Tan JC
Transpl Infect Dis; 2019 Feb; 21(1):e12998. PubMed ID: 30203504
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
7. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
8. Associations of high anti-CMV IgG titer with renal function decline and allograft rejection in kidney transplant patients.
Chen TH; Ou SM; Tarng DC
J Chin Med Assoc; 2022 Feb; 85(2):183-189. PubMed ID: 34882099
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
10. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
11. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics of Late-Onset Cytomegalovirus Infection After Kidney Transplantation.
Nuansri S; Kantachuvesiri S; Watcharananan SP; Thongprayoon C; Cheungpasitporn W; Bruminhent J
Transplant Proc; 2021 Sep; 53(7):2267-2271. PubMed ID: 34404538
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
14. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
[TBL] [Abstract][Full Text] [Related]
16. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
Cristelli MP; Felipe CR; Prizmic PSS; de Azevedo VFD; Viana LA; Tavares MG; Wagner de Castro Lima Santos D; de Paula MI; Medina-Pestana JO; Tedesco-Silva Junior H
Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
[TBL] [Abstract][Full Text] [Related]
17. Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (D-/R-).
Jorgenson MR; Descourouez JL; Yang DY; Stalter LN; Leverson GE; Parajuli S; Mandelbrot DA; Smith JA; Redfield RR
Transpl Infect Dis; 2021 Jun; 23(3):e13564. PubMed ID: 33449413
[TBL] [Abstract][Full Text] [Related]
18. Clinico-epidemiological characteristics of early- versus late-onset cytomegalovirus disease among renal transplant recipients: A two-decade experience.
Roy S; Kaul A; Bhadhuria DS; Prasad N; Garg A; Marak RSK; Patel MR; Behera MR; Kushwaha RS; Yachha M
Transpl Immunol; 2024 Jun; 84():102040. PubMed ID: 38565378
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Different Valgancyclovir Formulations in the Universal 6-Month Prophylaxis Against CMV Infection in Renal Transplant Recipients: A Randomized Single-Centre Study.
Basic-Jukic N; Furic-Cunko V; Hudolin T; Zimak Z; Kirincich J; Kastelan Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2019 Dec; 40(3):47-55. PubMed ID: 32109215
[TBL] [Abstract][Full Text] [Related]
20. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
